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Abstract 
Prostate cancer is one of major health concerns worldwide. Early detection for prostate cancer is very important 
since effective treatment is very limited for advanced prostate cancer. Molecular alteration happen prior to any 
morphological change, and Prostate Cancer Antigen 3 (PCA3) as the most specific marker for prostate cancer 
had been studied and proved its usefulness in detecting prostate cancer.  
------------------------------------------------------------------------ 
* Corresponding author.  
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However, the PCA3 level in peripheral blood remains unclear and only few research focused in the topic. 
Multiparametric Magnetic Resonance Imaging (mp-MRI) has superiorities in viewing prostate gland, without 
radiation exposure, also can be used without contrast injection. Early detection should avoid unnecessary 
medical examinations or interventions that will add up patients’ psychological burden, not to mention health 
care cost and logistic burdens. This pilot study will quantify PCA3 in blood, and the use of non-contrast mp-
MRI for prostate cancer detection. There were 19 patients who met inclusion and exclusion criteria. Evaluation 
with non-contrast mp-MRI used T2 Weighted Image (T2WI), and Diffusion Weighted Image (DWI). T2WI and 
DWI image category were based on PI-RADS version 2 criteria, while Apparent Diffusion Coefficient (ADC) 
value was acquired by defining lesion Region of Interest (ROI) in DWI Sequence. Summation of T2WI and 
DWI score result in total score. Peripheral blood samples were drawn and analyzed with Real Time Polymerase 
Chain Reaction (RT-PCR). Distribution table also independent t-test and Mann Whitney test were done, with 
Receiver Operating Curve (ROC) to find out the cut off value as secondary endpoints. Results revealed that, 
PCA3 mean level in prostate cancer is 10.996±1.901, mp-MRI median score in prostate cancer is 9 (8:10) with 
ADC median value is0.542 (0.339:0.768).There is statistically significant difference (p<0.05)in mp-MRI score 
and ADC value between prostate malignancy and non-malignancy (p=0.005, p=0.022), but there is no 
significant difference in PCA3 mean level for prostate malignancy and non-malignancy (p=0.851).In 
conclusion, PCA3 can be quantified from blood sample with mean level in prostate cancer is 10.996±1.901. 
Total score of non-contrast mp-MRI and ADC value can be used to differentiate prostate malignancy with non-
malignancy for prostate cancer detection. Further studies with more samples are needed to validate this study. 
Keywords: PCA3; PCR; quantitative test; non contrast mp;  MRI;  prostate cancer. 
1. Introduction  
Prostate cancer is the second common cancer in men, and fifth mortality cause due to cancer. Prostate cancer 
incidence will become 1.4 million in the world population, increase from 1.1 million in 2012 [1]. This condition 
is very concerning, moreover with the fact that there are limited therapy options available for advanced prostate 
cancer. Early detection is an important key factor to lower mortality and to avoid morbidity events related which 
will result in quality of life decrease. However, early detection should not cause unnecessary examination or 
treatment which could bring more burden to patients’ life aspects. Abnormal Digital Rectal Examination (DRE) 
and elevated Prostate Specific Antigen (PSA), followed by biopsy for histopathology evaluation is the standard 
prostate cancer diagnostic procedure in several guidelines commonly used by clinicians worldwide, that are 
National Institute for Health and Clinical Excellence (NICE), European Association of Urology (EAU), 
American Urological Association (AUA) and National Comprehensive Cancer Network (NCCN) [2-5]. 
Elevated PSA > 4 ng/ml has 80.6% sensitivity, 19.7% specificity and DRE for PSA > 4 ng/ml has 98% 
sensitivity, 9% specificity. Despite of good sensitivity, both DRE and PSA has low specificity that can lead to 
unnecessary biopsy recommendation [6,7]. Emerging modalities, mp-MRI with DWI and PCA3 might be used 
as early and reliable prostate cancer detection. Both modalities utilize molecular changes’ as an important 
parameter for prostate gland abnormalities. High resolution MRI imaging is best imaging modality without 
radiation effect that can improve prostate cancer detection; also to define its characterization, staging and 
treatment follow up. Multi-parametric MRI consists of several sequences with at least one more sequence apart 
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from the anatomical T2-weighted imaging [8]. PCA3 is a promising biomarker, since it is the most specific 
marker for prostate cancer [9,11]. There were previous studies regarding PCA3 showed positive result and 
support the roles of PCA3 in diagnosis of prostate cancer. Increased RNA levels in prostatic cancer cells can be 
detected in prostatic tissue, urine after prostatic massage and peripheral blood sample [10] Data from Sardareh 
HM and his colleagues showed PCA3 blood had 94.74% sensitivity with 81.82% specificity in detecting 
prostate cancer [12]. However, there were not much data about PCA3 from blood samples, yet we found it is the 
most practical method to do in daily practice for screening also to avoid patients’ discomfort because of prostate 
massage that is done before urine sample collection. Through this research, we aim to prove our hypothesis that 
mp-MRI score, ADC value and PCA3 mRNA level could differentiate between prostate malignancy and non-
malignancy. This research also has goal to find out the level of PCA3 in prostate cancer peripheral blood. Cut 
off values are secondary endpoints. 
2. Materials and Method 
Inclusion criteria are PSA level ≥ 4 ng/ml with or without nodular palpable prostate from DRE. Exclusion 
criteria are hypoglycemia, hyponatremia, deviant temperature, not cooperative/ fail to do MRI procedure, 
patients with MRI contra indications, claustrophobia and fail to provide biopsy result. There were 19 patients 
who met inclusion and exclusion criteria with characteristics defined in table 1 below
 Table 1: Patients Characteristics  
No Initial Age PSA Nodule 
(DRE) 




1 JLA 83 25.28 - 175 138 36.8 benign 
2 WSA 65 100 + 107 140 37 malignant 
3 RGU 68 10.76 - 102 142 36.6 malignant 
4 RHA 67 5.22 - 82 140 36.9 benign 
5 IRU 72 10.99 - 205 137 37.1 benign 
6 RSO 63 38.81 - 142 141 37.2 malignant 
7 CAK 69 10.11 - 94 140 37 benign 
8 JIS 67 5.3 - 91 145 36.9 malignant 
9 RTU 77 28.6 - 89 143 36.9 malignant 
10 BSU 68 4.49 - 157 138 36.7 malignant 
11 JKH 65 64.26 - 144 136 37.2 malignant 
12 SUH 74 5.77 - 97 134 37.2 malignant 
13 CHA 68 32.02 - 143 140 37.1 malignant 
14 BAT 59 10.98 - 99 139 36.8 malignant 
15 HTO 73 11.3 - 107 132 37 malignant 
16 RUD 73 100 - 107 139 36.6 malignant 
17 HNA 70 110.69 - 106 138 36.8 malignant 
18 FBO 75 9.5 - 121 140 36.9 malignant 
19 JPA 65 8.95 - 149 138 36.6 benign 
 
All patients underwent mp-MRI procedure using single calibrated MRI unit 1.5 Tesla (Avanto Fit), gradient 
strength 45 mT/m, slew rate 200 T/m/s, with parameter and specifications as described in the table.  
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Figure 1: Parameter of mp-MRI 
An endorectal prostate coil (Sentinelle Medical, Siemens AG) was inserted using analgesic gel prior to the exam 
to avoid pain and rectal spasm. Evaluation of mp-MRI used T2WI and DWI. Imaging category of T2WI and 
DWI based on Prostate Imaging-Reporting and Data System (PIRADS) version 2. Summation of both score 
resulted in total score of mp-MRI. ADC value was acquired by setting Region of Interest (ROI) in the specific 
lesion/area in the DWI sequence. ADC value would automatically generated by the MRI software, the error in 
placing the ROI would cause an error for the value as well. 
Peripheral blood was drawn and directly put in EDTA tube fornucleotide extraction followed by DNA 
amplification with primers Forward 5’-TATTCTGAAGTCAGAGTGTTCCAG-3’ and primer Reverse:5’-
CTTATTTCTCACCTCTGTATCATCAGG-3’ with housekeeping gene b2MF:5-
GTCTTTCTATCTCTTGTACTACACTGAA-3 and b2MR: 5 – AACTATCTTGGGCTGTGACAAAG -3 using 
Qiagen SYBR-GREEN qPCR Mastermix (QIAGEN, Germany). Each reaction contained 7.5 ml of qPCR 
mastermix, 5 pM of each forward and reverse primer and 5 ml of the diluted cDNA template.  
The following cycling conditions were applied: 95oC for 15 minutes, followed by 45 cycles of 95oC   for each 
20 seconds period, 58–59oC   for 20 seconds and 72oC for 20 seconds. Data for each cycle was acquired at the 
elongation step and each reaction was carried out in triplicate. Relative gene expression levels were calculated 
using methodology described in Pfaffl [13,14]. 
3. Results 
Mean age for prostate cancer patients are 69.33 ± 5.348 years old. Multifocal lesions were detected in more 
patients (58.3%) rather than solitary lesion in mp-MRI images evaluation. There were 11 lesions out of 16 
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lesions (68.75%) located in peripheral zone, while 5 lesions were located in transitional zone (31.25%). 
PCA3 data was normally distributed and analyzed for means comparison using independent t-test, while mp-
MRI score and ADC value were analyzed using Mann Whitney test. 
Table 2: Results’ Statistic Analysis 
 Mean SD p 
Malignant PCA3 10.996 1.901 0.851 
Benign PCA3 10.743 3.136  
 Median Min:Max p 
Malignant mp-MRI score 9 8:10 0.005 
Benign mp-MRI score 2 2:9  
Malignant ADC value 0.542 0.339:0.768 0.022 
Benign ADC value 0.987 0.450:1.569  
 
 
Figure 2: ROC Curve of mp-MRI Total Score (left) and ADC Value (right) 
Cut off values for mp-MRI total score and ADC value were defined with ROC curve. Both ROC curve has 
excellent Area Under the Curve (AUC) that are 0.869 and 0.821 respectively. Best sensitivity and specificity is 
determined by coordinate points of the ROC. Total score of mp-MRI 7 through highest indicates malignancy 
with 100% sensitivity and 71.4% specificity while ADC value bigger or equal than 0.684 indicates non-
malignancy with 71.4% sensitivity and 91.7% specificity. 
4. Discussion 
The results shown at table 2 above prove that mp-MRI total score from T2WI and DWI score also ADC value 
could be used to differentiate prostate cancer from other prostate benign conditions. Previous studies on mp-
MRI confirmed its use to predict the malignancy probability, standardized through PI-RADS version 1 and 2 
[15]. Even though the research used less sequence to avoid contrast injection, it still can be used to differentiate 
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prostate cancer. Previous studies also mentioned that DWI and T2WI sequences have good sensitivity and 
specificity in detecting prostate cancer [16,17]. 
Free water molecules are in constant random motion, known as Brownian motion, which the motion of water 
molecules within the cellular microenvironment is impeded by their interaction with cellular compartments and 
thermal energy. Apparent diffusion coefficient (ADC) measures diffusion rate of water molecules within a 
tissue. Multipoint b value analyses increase the accuracy of the calculated ADC at the expense of increased 
scanning time and decrease in signal to noise ratio (SNR) [18, 19]. ADC is mainly influenced by 
cellular/extracellular volume ratio, composition of extracellular space, and temperature [20]. The same effect on 
the speed of diffusion is observed in hypoglycemia andhyponatremia in which membrane depolarization makes 
excess extracellular water molecules move into the cells [21,22]. ADC value results in this study could not be 
applied instantly, because ADC is influenced by many internal (human body) factors and external (equipment 
setting) factors. To refer the same ADC value, there are several adjustments should be made according to this 
study specifications. Based on study done by Sato and his colleagues it also stated that cancerous tissue tend to 
have lower ADC value, similar to our study  [23]. 
Molecular changes precede prostate cancer morphological alterations [10]. PCA3 mRNA could be detected in 
peripheral blood with mean level of 10.996±1.901, however it didn’t have significant statistical analysis 
between malignancy and non-malignancy group. This result is in contrast with previous research that mentioned 
statistical significant difference between prostate cancer and other benign prostate conditions. Sardareh and his 
colleagues found the mean level of prostate cancer patients is 7.18 ±1.02 [12] ). There are several factors such as 
epigenetic and pathway signal error that could play role in this PCA3 results [11, 24]. PCA3 is over expressed in 
prostate cancer, justifies the high level of PCA3 mRNA in prostate cancer blood [25-29]  
There are only few patients willing to do biopsy and therefore we had lack of data. More studies with bigger 
sample are still needed to validate this research. 
5. Conclusion 
PCA3 can be quantified from blood sample with mean level in prostate cancer is 10.996±1.901. Total score of 
non-contrast mp-MRI and ADC value can be used to differentiate prostate malignancy with non-malignancy for 
prostate cancer detection. 
References 
 [1] International Agency for Research on Cancer (2016) Prostate Cancer Estimated Incidence, Mortality 
and Prevalence Worldwide in 2012, World Health Organization. doi: 
http://globocan.iarc.fr/Default.aspx. 
 [2] Carter, B., Albertsen, P., Barry, M., Etzioni, R., Freedland, S., Greene, K., Holberg, L., Kantoff, P., 
Konety, B., Murray, M., Person, D. and Zietman, A. (2013) Early Detection of Prostate Cancer: Aua 
Guideline, American Urological Association Education and Research. doi: 10.1111/bju.12318. 
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2017) Volume 32, No  3, pp 365-373   
371 
 
 [3] Heidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., Van Der Kwast, T., Mason, M., 
Matveev, V., Wiegel, T., Zattoni, F. and Mottet, N. (2014) ‘EAU guidelines on prostate cancer. Part 1: 
Screening, diagnosis, and local treatment with curative intent - Update 2013’, European Urology. 
European Association of Urology, 65(1), pp. 124–137. doi: 10.1016/j.eururo.2013.09.046. 
 [4] National Institute for Health and Clinical Excellence (2014) ‘Prostate cancer : diagnosis and 
management’, (Accessed: January 2017). 
 [5] Carroll, P. R., Kellogs, J. P., Androile, G., Banson, R. R., Castle, E. P., Catalona, W. J. and Dahl, D. M. 
(2016) Prostate Cancer Early Detection version 2, National Comprehensive Cancer Network. Available 
at: https://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf (Accessed: 13 
December 2016). 
[6] Vukotic, V., Cerovic, S., Kozomara, M. and Lazic, M. (2005) ‘The predictive value of PSA in diagnosis 
of prostate cancer in non-screened population’, Acta Chirugica Iugoslavica, 54(4), pp. 81–86. 
 [7] Aslan, G., Irer, B., Cimen, S., Goktay, Y., Celebi, I., Tuna, B. and Yorukoglu, K. (2011) ‘The 
Performance of Abnormal Digital Rectal Examination for the Detection of Prostate Cancer at Stratified 
Prostate Specific Antigen Levels’, Open Journal of Urology, 1(4), pp. 67–71. doi: 
10.4236/oju.2011.14014. 
[8] Mohler, J. L., Armstrong, A. J. and and Prostate Cancer Panel Member (2016) NCCN Clinical Practice 
Guidelines in Oncology: Prostate Cancer, Prostate Cancer version 3. doi: 10.1016/B978-0-12-800077-
9.00059-1. 
[9] Bussemakers, M. J. G., Van Bokhoven, A., Verhaegh, G. W., Smit, F. P., Karthaus, H. F. M., Schalken, 
J. A., Debruyne, F. M. J., Ru, N. and Isaacs, W. B. (1999) ‘DD3: A new prostate-specific gene, highly 
overexpressed in prostate cancer’, Cancer Research, 59(23), pp. 5975–5979. doi: 10.1038/ncb2161. 
[10] Neves, A. F., Dias-Oliveira, J. D. D., Araújo, T. G., Marangoni, K. and Goulart, L. R. (2013) ‘Prostate 
cancer antigen 3 (PCA3) RNA detection in blood and tissue samples for prostate cancer diagnosis’, 
Clinical Chemistry and Laboratory Medicine, 51(4), pp. 881–887. doi: 10.1515/cclm-2012-0392. 
 [11] Wang, Y., Liu, X.-J. and Yao, X.-D. (2014) ‘Function of PCA3 in prostate tissue and clinical research 
progress on developing a PCA3 score.’, Chinese journal of cancer research = Chung-kuo yen cheng 
yen chiu, 26(4), pp. 493–500. doi: 10.3978/j.issn.1000-9604.2014.08.08. 
[12] Sardareh, H. M., Goodarzi, M. T., Yadegar-Azari, R., Poorolajal, J., Mousavi-Bahar, S. H. and 
Saidijam, M. (2014) ‘Prostate cancer antigen 3 gene expression in peripheral blood and urine sediments 
from prostate cancer and benign prostatic hyperplasia patients versus healthy individuals’, Urology 
Journal, 11(6), pp. 1952–1958. doi: <Go to ISI>://WOS:000347658900005. 
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2017) Volume 32, No  3, pp 365-373   
372 
 
 [13] Pfaffl, M. W. (2001) ‘A new mathematical model for relative quantification in real-time RT-PCR.’, 
Nucleic acids research, 29(9), p. e45. doi: 10.1093/nar/29.9.e45. 
Röthke, M., Blondin, D., Schlemmer, H. and Franiel, T. (2013) ‘PI-RADS Classification : Structured 
Reporting for MRI of the Prostate’, pp. 30–38. 
 [14] Clarke, R. A., Zhao, Z., Guo, A. Y., Roper, K., Teng, L., Fang, Z. M., Samaratunga, H., Lavin, M. F. 
and Gardiner, R. A. (2009) ‘New genomic structure for prostate cancer specific gene PCA3 within 
BMCC1: Implications for prostate cancer detection and progression’, PLoS ONE, 4(3). doi: 
10.1371/journal.pone.0004995. 
[15] American College of Radiology Working Group (2015) ‘PI-RADS Prostate Imaging – Reporting and 
Data System’, in American College of Radiology. 
[16] Dickinson, L., Ahmed, H. U., Allen, C., Barentsz, J. O., Carey, B., Futterer, J. J., Heijmink, S. W., 
Hoskin, P., Kirkham, A. P., Padhani, A. R., Persad, R., Puech, P.,  
[17] Zhang, Z.-X., Yang, J., Zhang, C.-Z., Li, K.-A., Quan, Q.-M., Wang, X.-F., Wang, H. and Zhang, G.-
X. (2014) ‘The Value of Magnetic Resonance Imaging in the Detection of Prostate Cancer in Patients 
with Previous Negative Biopsies and Elevated Prostate-specific Antigen Levels: A Meta-analysis.’, 
Academic radiology. Elsevier Ltd, 21(5), pp. 578–89. doi: 10.1016/j.acra.2014.01.004 
[18] Malayeri, A. A., El Khouli, R. H., Zaheer, A., Jacobs, M. A., Corona-Villalobos, C. P., Kamel, I. R. 
and Macura, K. J. (2011) ‘Principles and Applications of Diffusion-weighted Imaging in Cancer 
Detection, Staging, and Treatment Follow-up’, Radiographics, 31(6), pp. 1773–1791. doi: 
10.1148/rg.316115515. 
[19] Ghai, S. and Haider, M. A. (2015) ‘Multiparametric-MRI in diagnosis of prostate cancer.’, Indian 
journal of urology : IJU : journal of the Urological Society of India, 31(3), pp. 194–201. doi: 
10.4103/0970-1591.159606. 
[20] Fornasa, F. (2014) ‘Diffusion-weighted Magnetic Resonance Imaging : What Makes Water Run Fast 
or Slow ?’, 1(2), pp. 1–7. 
 [21] Sevick, R. J., Kanda, F., Mintorovitch, J., Arieff, A. I., Kucharczyk, J., Tsuruda, J. S., Norman, D. and 
Moseley, M. E. (1992) ‘Cytotoxic brain edema: assessment with diffusion-weighted MR imaging.’, 
Radiology, 185(3), pp. 687–690. doi: 10.1148/radiology.185.3.1438745. 
22] Matsumoto, Y., Kuroda, M., Matsuya, R., Kato, H., Shibuya, K., Oita, M., Kawabe, A., Matsuzaki, H., 
Asaumi, J., Murakami, J., Katashima, K., Ashida, M., Sasaki, T., Sei, T., Kanazawa, S., Mimura, S., 
Oono, S., Kitayama, T., Tahara, S. and Inamura, K. (2009) ‘In vitro experimental study of the 
relationship between the apparent diffusion coefficient and changes in cellularity and cell morphology’, 
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2017) Volume 32, No  3, pp 365-373   
373 
 
Oncology reports, 22, pp. 641–648. doi: 10.3892/or_00000484. 
 [23] Sato, C., Naganawa, S., Nakamura, T., Kumada, H., Miura, S., Takizawa, O. and Ishigaki, T. (2005) 
‘Differentiation of noncancerous tissue and cancer lesion by apparent diffusion coefficient values in 
transition and peripheral zones of the prostate’, Journal of Magnetic Resonance Imaging, 21(3), pp. 
258–262. doi: 10.1002/jmri.20251. 
 [24] Beermann, J., Piccoli, M.-T., Viereck, et al. (2016) ‘Non-coding RNAs in Development and Disease: 
Background, Mechanisms, and Therapeutic Approaches.’, Physiological reviews, 96(4), pp. 1297–325. 
doi: 10.1152/physrev.00041.2015. 
[25] De Kok, J. B., Verhaegh, G. W., Roelofs, R. W., Hessels, D., Kiemeney, L. A., Aalders, T. W., 
Swinkels, D. W. and Schalken, J. A. (2002) ‘DD3PCA3, a very sensitive and specific marker to detect 
prostate tumors’, Cancer Research, 62(9), pp. 2695–2698. doi: 10.1016/s0022-5347(01)65160-7. 
 [26] Schalken, J. A., Hessels, D. and Verhaegh, G. (2003) ‘New targets for therapy in prostate cancer: 
Differential display code 3 (DD3PCA3), a highly prostate cancer-specific gene’, Urology, 62(5 
SUPPL. 1), pp. 34–43. doi: 10.1016/S0090-4295(03)00759-3. 
[27] Auprich, M., Bjartell, A., Chun, F. K. H., De La Taille, A., Freedland, S. J., Haese, A., Schalken, J., 
Stenzl, A., Tombal, B. and Van Der Poel, H. (2011) ‘Contemporary role of prostate cancer antigen 3 in 
the management of prostate cancer’, European Urology, 60(5), pp. 1045–1054. doi: 
10.1016/j.eururo.2011.08.003. 
 [28] Punwani, S., Sohaib, A., Tombal, B., van der Meulen, J., Villers, A. and Emberton,  M. (2013) 
‘Clinical applications of multiparametric MRI within the prostate cancer diagnostic pathway’, Urologic 
Oncology: Seminars and Original Investigations, 31(3), pp. 285–287. doi: 
10.1016/j.urolonc.2012.02.004. 
[29] Day, J. R., Jost, M., Reynolds, M. A., Groskopf, J. and Rittenhouse, H. (2011) ‘PCA3: From basic 
molecular science to the clinical lab’, Cancer Letters. Elsevier Ireland Ltd, 301(1), pp. 1–6. doi: 
10.1016/j.canlet.2010.10.019. 
 
 
